Background. Little is known about the long-term recurrence risk for primary hyperparathyroidism after immediately "curative" parathyroidectomy. This study aimed to evaluate the risk of recurrent hyperparathyroidism in the 10 years after operation. Method. We retrospectively identified patients with sporadic primary hyperparathyroidism undergoing initial parathyroidectomy between November 1, 2000 and June 30, 2005. Recurrence was defined as serum calcium >10.2 mg/dL after 6 months from operation. Kaplan-Meier estimates and Cox proportional hazards were used to evaluate disease-free survival and predictors of recurrence. Results. We evaluated 196 patients with a 14.8% 10-year recurrence rate. Median time to recurrence was 6.3 years (interquartile range 3.4-10.8 years), and 34.5% of all recurrences were identified >10 years after operation. There was no difference in recurrence between open and minimally invasive operation (P = .448). Double adenomas (P = .006), intraoperative parathyroid hormone drop <70% (P = .015), and young age (P = .032) were predictive of disease recurrence. Multivariable analysis demonstrated that older age was protective against recurrence (hazard ratio 0.97, 95% confidence interval 0.94-0.99, P = .034), while double adenomas (hazard ratio 3.52, 95% confidence interval 1.23-10.08, P = .019) were an independent predictor for recurrence. Conclusion. The long-term recurrence rate for sporadic primary hyperparathyroidism after "curative" parathyroidectomy is likely greater than reported. With over one-third of our institutional recurrences at >10 years after the initial operation, long-term follow-up is essential. (Surgery 2017;161:54-61.) 
Background. Little is known about the long-term recurrence risk for primary hyperparathyroidism after immediately "curative" parathyroidectomy. This study aimed to evaluate the risk of recurrent hyperparathyroidism in the 10 years after operation. Method. We retrospectively identified patients with sporadic primary hyperparathyroidism undergoing initial parathyroidectomy between November 1, 2000 and June 30, 2005. Recurrence was defined as serum calcium >10.2 mg/dL after 6 months from operation. Kaplan-Meier estimates and Cox proportional hazards were used to evaluate disease-free survival and predictors of recurrence. Results. We evaluated 196 patients with a 14.8% 10-year recurrence rate. Median time to recurrence was 6.3 years (interquartile range 3.4-10.8 years), and 34.5% of all recurrences were identified >10 years after operation. There was no difference in recurrence between open and minimally invasive operation (P = .448). Double adenomas (P = .006), intraoperative parathyroid hormone drop <70% (P = .015), and young age (P = .032) were predictive of disease recurrence. Multivariable analysis demonstrated that older age was protective against recurrence (hazard ratio 0.97, 95% confidence interval 0.94-0.99, P = .034), while double adenomas (hazard ratio 3.52, 95% confidence interval 1.23-10.08, P = .019) were an independent predictor for recurrence. Conclusion. The long-term recurrence rate for sporadic primary hyperparathyroidism after "curative" parathyroidectomy is likely greater than reported. With over one-third of our institutional recurrences at >10 years after the initial operation, long-term follow-up is essential. University of Alabama at Birmingham, Birmingham, AL THE INCIDENCE OF PRIMARY HYPERPARATHYROIDISM (1HPT) is steadily increasing, and parathyroidectomy is the only curative treatment. Recent data from the Kaiser-Permanente system revealed a 3-fold increase in 1HPT diagnosed during their study period from 1995-2010, across sexes and races. 1 Previous studies have shown that parathyroidectomy for 1HPT is curative in >95% of cases when performed by an experienced surgeon. [2] [3] [4] In addition, prospective observation has confirmed that parathyroidectomy not only results in sustained improvements in short-term bone mineral density but also produces a sustained benefit over time, which is critically important to older patients at risk for osteoporosis and fractures. 5 Despite the high cure rate after parathyroidectomy, recurrence of 1HPT remains a clinical challenge. A better understanding of recurrence risk has significant implications on operative strategy and duration of postoperative follow-up. Recurrence can be due to anatomic factors, such as ectopic or supernumerary glands, or biologic factors, such as genetics and environmental exposure, and rarely parathyroid cancer. 6 Previous studies that have prospectively evaluated recurrence after parathyroidectomy occurred prior to several modern advances in surgical technique, such as intraoperative parathyroid hormone (PTH) monitoring, the use of minimally invasive parathyroidectomy, and the development of more advanced imaging modalities for preoperative gland localization.
Walgenbach et al 3 prospectively followed a group of patients in Germany from 1987-1998 with 1HPT for a median of 2 years. They report a 98% cure rate after operation and a surprising 4.7% rate of permanent hypoparathyroidism. A prospective Swedish study of patients who had an operation for 1HPT from 1953-1982 reported an overall recurrence rate of 7% in patients, including single-or multigland disease, with instances of recurrence reported at >20 years after parathyroidectomy. 7 Data on long-term rates of 1HPT recurrence in a more recent group of patients, however, remain lacking.
The goal of this study was to evaluate the 10-year risk of recurrent 1HPT after parathyroidectomy in a contemporary cohort of patients. We additionally sought to identify factors that are associated with risk of recurrence.
METHODS
We used the University of Wisconsin parathyroid operation database to retrospectively identify all patients undergoing parathyroidectomy between November 1, 2000, and June 30, 2005. We excluded all patients with secondary or tertiary hyperparathyroidism or a known family history of parathyroid disease. We also excluded patients with mediastinal adenomas requiring full or partial sternotomy and those with parathyroid cancer. Patients undergoing reoperative parathyroid or neck operation were also excluded.
Persistent disease was defined as elevated serum calcium within 6 months of operation. Operative cure was therefore defined as having normal serum calcium values after 6 months after operation. Patients with persistent disease and those missing serum calcium levels after 6 months from operation were also excluded from analysis. The remaining 196 patients were classified as having undergone a curative parathyroidectomy for their initial, sporadic 1HPT (Fig 1) .
We then examined predictors of 1HPT recurrence, which was defined as a serum calcium $10.2 mg/dL, the upper limit of normal in our laboratory system, at any point beyond 6 months after parathyroidectomy. To be included in our study cohort, all patients had $1 serum calcium level drawn after 6 months from parathyroidectomy. Medical records were extensively scrutinized when available to rule out causes of hypercalcemia other than recurrent hyperparathyroidism, including calcium oversupplementation, thiazide use, paraneoplastic syndrome, or worsening renal function. Patient deaths during the follow-up period were confirmed either through the electronic medical record or through crossreferencing with the Federal Social Security Death Index. Follow-up times were calculated from the date of operation to the date of the patient's last available serum calcium level. Patients were censored at the time of death or last reported serum calcium.
Cause of 1HPT was categorized as single adenoma, double adenoma, or hyperplasia based on the number of glands resected and was subsequently confirmed on final operative pathology. Patients were categorized as either undergoing unilateral, minimally invasive parathyroidectomy (MIP), or bilateral neck exploration via a bilateral approach. As we retrospectively examined this cohort, this designation was based on the actual operation performed rather than intention to treat.
Comparisons between groups were made using v 2 for proportions and Student t tests for means.
We evaluated time to recurrence using the methods of Kaplan and Meier with the log-rank test for comparison. We then used Cox regression in univariate analysis to identify independent predictors of recurrence risk. Applying a threshold of P < .1 on univariate analysis and additionally including operative approach, a clinically significant factor, a multivariate model was constructed. Cox regression was then used to divide patients into age quartiles to specifically examine recurrence-free survival by age group. All statistical calculations were performed using SPSS software (IBM SPSS Statistics for Windows, Version 22.0; IBM Corp, Armonk, NY).
RESULTS

Patient demographics.
A total of 196 patients met inclusion criteria with an overall median follow-up time of 9.2 years (interquartile range [IQR] 5.4-10.9 years). A total of 193 (98.5%) patients presented with hypercalcemia, serum calcium $10.2 mg/dL. The majority of patients were women, with single adenoma found in 80.6% of patients. Most patients also underwent a preoperative localization study, such as sestamibi scanning or neck ultrasonography (Table I) . A total of 3 patients (1.5%) underwent concomitant thyroid operation during parathyroidectomy. The median age of our cohort was 61 years (IQR 51-70 years). A total of 46 (23.5%) patients died during this extended study period, most often from cardiovascular and neoplastic processes. Only 3 (6.5%) patients in the deceased cohort were categorized as having 1HPT recurrence, none of these patients had a known malignancy at the time of recurrence or at death.
Time to recurrence. The 10-year recurrence rate in our cohort was 14.8% (29/196), with a median time to recurrence of 6.3 years (IQR 3.4-10.8 years). We found that 41.4% of recurrences were detected by 5 years and 65.5% by 10 years. Additionally, 34.5% of all recurrences appeared $10 years after initial parathyroidectomy. Of the 29 patients who had recurrence, 16 (55%) patients underwent reoperation after successful localization at a median time of 8.71 years ± 1.06 years after initial parathyroidectomy.
The cure rate after reoperation was 87.5% (14/ 16) with one patient lost to follow-up and one patient with persistent disease. A total of 7 (24%) patients had incomplete medical records with respect to physician encounters, and 4 patients (14%) refused reoperation. One patient was not localized, and the final patient with recurrence was diagnosed recently and is currently discussing treatment plans.
Factors associated with recurrence. There was no difference in recurrence rates for patients who had MIP or bilateral exploration (P = .448). Five year, disease-free survival in patients undergoing unilateral MIP was 91.8% vs 97.9% in the bilateral group. The recurrence curves converge at 10 years, however, with a disease-free survival for the MIP group of 87.9% vs 87.4% in the bilateral group (Fig 2, A) .
Examining potential predictors of recurrence, we found that double adenomas (DA) were more likely to recur than single adenomas (P = .006) but not hyperplasia (P = .525; Fig 2, B) . Additionally, younger age (P = .032) and a drop in intraoperative parathyroid hormone (IoPTH) < 70% were predictive of disease recurrence (P = .015). were protective against recurrence. On the other hand, DA (HR 3.52, 95% CI 1.23-10.08, P = .019) was an independent predictor of recurrence (Table II) .
Lastly, to further examine the impact of age on recurrence, patients were divided into age quartiles and stratified according to disease etiology and IoPTH drop >70%. Only single adenoma provided adequate sample size for this subgroup analysis. The curves for the oldest patient quartile, age $70 years, show a clear separation that trends toward improved recurrence-free outcomes compared to the remaining age quartiles (Fig 3,  A and B) . This further confirms the protective effect of older age on 1HPT recurrence. The improved trend in the oldest patients, however, was not statistically significant for either single adenoma (P = .311) or IoPTH drop >70% (P = .152).
DISCUSSION
Through extended follow-up of this contemporary cohort, we report a 14.8% recurrence rate for sporadic 1HPT after apparently curative parathyroidectomy. In our series, more than one-third of the recurrences occur $10 years after initial operation, highlighting the importance of Results presented as median (25th; 75th percentile), mean ± SEM (standard error of the mean), or n (%). BMI, Body mass index; preop, preoperative. long-term follow-up for these patients. Our practice is to recommend annual serum calcium checks, however, given the age and comorbidities of the patient; the frequency and duration of calcium surveillance may be shortened or extended. Though patients may seem asymptomatic at the time of detected recurrence, 1HPT is often associated with vague symptomatology and, more importantly, negative effects on bone health that can all be improved with parathyroidectomy. 8 Retrospective studies that have looked at outcomes after parathyroidectomy for 1HPT have suffered from lack of long-term follow-up, with reported mean follow-up times ranging from 0-7.4 years. 9, 10 Reported recurrence rates in these studies range from 0% 11 to 5.2%. 10 We report here a much greater incidence of recurrence when patients are followed for a greater period of time. This may be in part due to our definition of recurrence based on hypercalcemia alone. However, as 98% of our cohort presented with preoperative hypercalcemia, this marker seems a reasonable surrogate for recurrence events even in the absence of available postoperative serum PTH levels. Therefore, the long-term recurrence rate for 1HPT after apparently curative parathyroidectomy is likely to be greater than previously reported. Parathyroid operations are safe and associated with excellent outcomes without decreased longterm survival. 12, 13 The increasing popularity of MIP, a unilateral neck exploration after appropriate preoperative localization, has sparked much debate over the optimal operative approach for sporadic hyperparathyroidism. Although some have abandoned this approach and prefer to perform a bilateral exploration on all patients without reported increases in morbidity or operative time, 14 other groups continue to offer MIP to appropriately selected patients. 15, 16 Long-term outcomes on 184 patients with sporadic 1HPT with preoperative localization reported a 1.6% incidence of persistent hypercalcemia after operation, with no recurrences at mean follow-up of approximately 5 years. 17 A recent, randomized clinical trial comparing unilateral versus bilateral cervical exploration for 1HPT with a primary end point of persistent disease concluded a similar failure rate of 2% with a mean follow-up time of 23 months. 18 Five patients with 1HPT were excluded from our study due to persistent disease. Of these, 3 patients had preoperative localization of whom 2 underwent MIP with the last being converted from MIP to bilateral exploration.
Our group has also previously reported the equivalence of either MIP or a bilateral approach in selected patients in the short-term 19 ; however, all studies have failed to look at long-term recurrence rates. This study demonstrates that operative approach is not independently predictive of longterm recurrence (P = .448) in patients with 1HPT. Due to the low number of events and the diminishing number at risk with longer duration of follow-up, we may be failing to detect if such a difference truly exists beyond 12 years where the curves diverge. Extended follow-up to 10 years, however, demonstrates equivalent recurrence-free survival regardless of operative approach, which suggests that bilateral exploration is not the absolute solution in adenoma recurrences.
DA is the least commonly identified form of 1HPT with reported rates ranging from 0-11.8%. 20 DA is particularly challenging to detect both preoperatively and intraoperatively. 21 Preoperative localization often fails to distinguish between 2-gland and multiglandular disease. 20 Early recommendations were to perform bilateral exploration on all of these patients with selective resection of abnormal glands. 20 Our recurrence-free survival analysis found all recurrences for DA to occur within the first 5 years of follow-up, questioning the need for bilateral exploration in this subset of patients.
A retrospective series of patients with 1HPT due to DA found a 50% drop in IOPTH did not reliably predict cure in 55% of cases despite a bilateral neck exploration in all patients. 22 Therefore, it is not entirely surprising that we found DA to be highly predictive in multivariate analysis of having 1HPT recurrence during a 10-year follow-up period. Finding DA during parathyroidectomy, therefore, should increase suspicion when evaluating for operative cure and during subsequent follow-up for recurrence.
Our study has several limitations. First is the retrospective nature of our data collection, with almost 20% of our study population excluded due to lack of follow-up beyond 6 months during the decade long period of interest. It is unclear whether patients with incomplete follow-up would lead to over-or underestimation of recurrent hyperparathyroidism. Second, our definition of recurrence was based on hypercalcemia alone. While the records were carefully scrutinized to exclude other causes of hypercalcemia, examining serum calcium and PTH concurrently is a more accurate picture of disease status.
Serum PTH levels were rarely drawn, however, especially in patients with normal serum calcium levels. Therefore we may be underestimating the true recurrence rate without the available serum PTH values. The importance of long-term followup in patients with sporadic 1HPT should also take into consideration expected life-years. The median age at time of operation for our cohort was 61 years (IQR 51-70 years). Advanced age is not a contraindication for parathyroid operation, [23] [24] [25] but life expectancy is certainly an important factor when it comes to duration and frequency of continued surveillance. Notwithstanding these limitations, we have demonstrated the importance of having long-term follow-up after parathyroidectomy for sporadic 1HPT.
In conclusion, our cohort of 196 patients who underwent apparently curative parathyroidectomy for sporadic 1HPT between 2000-2005 demonstrated an overall recurrence rate of 14.8%, with over a third of these recurrences diagnosed >10 years after initial operation. While a definite long-term recurrence rate after parathyroidectomy is currently unknown, this highlights the importance and necessity of long-term follow-up for 1HPT patients. You mentioned that significant factors are greater than 70% drop. I know your group along with our group also likes to see that greater than 50% drop into normal range and actually less than 40 of an absolute PTH number that we also like to use, and you published that in Wisconsin. What percentage of your patients had a final PTH of less than 40 that ended up recurring? Number 2, you mentioned the double adenomas. What percentage of those double adenomas---were they 2 double uppers, 2 double lowers, contralateral sides, same side? Will it make a difference where you found those double adenomas? Dr Irene Lou: To answer your first question, we chose our cut-off at 70% based on the median. So our median was around 65%. So we looked at our data at 60%, 70%, 80% cut-off, and 70% was the best of our data. So I do not know if any of our patients dropped to less than 40%, but we do use the Miami criterion of a drop of 50% of intraoperative parathyroid hormone intraoperatively to predict cure. So I would imagine 100% of our patients dropped at least the 50%. Otherwise, they would not have left the operating room, because we excluded our patients with persistent disease in looking at this cohort.
Dr Kepal N. Patel (New York, NY): Absolute number of 40, not 40%. It was an absolute number of 40, not 40%.
Dr Irene Lou: I see. The short answer is I do not know. Post operative PTH levels were difficult to obtain. PTH levels were not one of the things that we were able to look at long term. Patients with normocalcemia did not have PTH levels drawn, so we were not able to look at that. But to your question for double adenomas, half of our patients with double adenomas had a single, one-sided exploration, so both glands were on the same side. And the other half of our patients actually had an open exploration for glands, so either upper-upper or lower-lower on either side, contralateral side.
Dr Samuel K. Snyder (Temple, TX): This is an excellent study. It is telling us that we need to follow our patients much longer than perhaps we did previously. But your definition is normocalcemia at 6 months, and that is the true definition. As you know, we all see patients that have normal calcium and still have a residual elevated parathyroid hormone level. So I am looking at your recurrences, and I am wondering if you looked at that 6-month-plus parathyroid hormone level and could see any differences in the patients that recurred versus those that did not. Secondly, I am interested in your vitamin D levels. You know, we find there is a high prevalence of vitamin D deficiency in primary hyperparathyroidism. We are supposed to correct that and tell our patients to maintain that. In your recurrences, did you see recurrent vitamin D deficiency? In other words, they were not taking the recommended vitamin D? And how often did that happen? Dr Irene Lou: Unfortunately, we did not have vitamin D data level for our cohorts. PTH was not necessarily drawn on the majority of our patients. We especially wanted to correlate the PTH with the most recent serum calcium in order to get a better assessment of what their biochemical profile was. So in looking at followup data, we had calcium on only 196 patients, 10 years out, and it was very difficult to get the corresponding parathyroid hormone levels, so we were not capturing the entire picture of recurrence for patients who had hypercalcemia in recurrence, so I think that Vitamin D was probably even more so underestimating recurrence since we do not even have the PTH numbers.
Dr Marco Raffaelli (Rome, Italy): I am only concerned about the definition of recurrence on serum calcium levels, I think, is a good definition for recurrence.
And the question with regard to the diagnosis of double adenoma, were these reviewed by pathology after recurrence or not?
Dr Irene Lou: For your second question, in order to classify all of our patients in the etiology categories, we also looked at the confirmation with pathology. To your first point, which was following patients for much longer?
Dr Marco Raffaelli (Rome, Italy): Was it based only on serum calcium levels? Dr Irene Lou: 10.2 is what the limit of normal is in our system, and in order to perform the capture of our data, we looked at hypercalcemia and, attempted to look at parathyroid hormone.
